mov2improve icon

1.0.0 by Innopulse Asesores Tecnologicos SL


Sep 2, 2022

About mov2improve

Your muscle Glycogen Storage Disease

Mov2improv App is the first APP ever developed for McArdle disease patients or any other muscle glycogenosis. This APP can measure the number of steps per day, minutes of exercise per day, number of myoglobinuria episodes per week, heart rate, body temperature and pain (scale 1 to 10). Additionally, this APP includes an alarm to advise the patients when a certain threshold in the measured variables has been surpassed. The APP/AI tool will offer patients the required information, support and feedback to safely manage their condition on a daily basis. The usage of the APP/AI tool will facilitate patient’s empowerment in exercise therapies compliance and self-evaluation in daily life activities, which will reduce the number of control visits to the medical specialists and increase their confidence in performing regular exercise activity. Additionally, the constant recording of physiologic data and exercise responses from each patient using this tool will provide dynamic information of the progression of the disease for each patient that will help clinicians and exercise physiologists to adapt their clinical recommendations to the individual necessities

What's New in the Latest Version 1.0.0

Last updated on Sep 2, 2022

Minor bug fixes and improvements. Install or update to the newest version to check it out!

Translation Loading...

Additional APP Information

Latest Version

Request mov2improve Update 1.0.0

Requires Android

7.0

Available on

Get mov2improve on Google Play

Show More

mov2improve Screenshots

Comment Loading...
Searching...
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Subscribed Successfully!
You're now subscribed to APKPure.
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Success!
You're now subscribed to our newsletter.